Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02140645 · ClinicalTrials.gov registry record
Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 166,613
- Enrollment target
NCT02140645 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 166,613 participants.
The verdict
NCT02140645 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 166,613 participants
- Enrollment target
Study Summary
The objective of this study is to identify EMR-based clinical covariates and quantify their association with the prescribing of each specific type 2 diabetes (T2DM) medication under investigation. This will include an assessment of how well these covariates are captured through claims data proxies, and their potential to confound comparative research of T2DM medications.
Interventions
- DRUG linagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166,613 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02140645
The ClinicalTrials.gov registry entry for NCT02140645 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 166,613 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which linagliptin is the first listed.
NCT02140645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02140645 about?
NCT02140645 is a clinical study titled "Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy". The objective of this study is to identify EMR-based clinical covariates and quantify their association with the prescribing of each specific type 2 diabetes (T2DM) medication under investigation. This will include an assessment of how well these covariates are captured through claims data proxies, ...
What is the current status of trial NCT02140645?
This trial is currently completed. The enrollment target is 166,613 participants. The study started on 2014-05. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02140645?
The interventions under investigation include: linagliptin (DRUG).
Who is sponsoring clinical trial NCT02140645?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.